Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Penn State University
With
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Chronic HS for \> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS
Localizes to skin folds including any of axillx, breast, abdomen and groin
active disease
Negative pregnancy test within 7 days before the first dose of study drug
Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study
You may not be if
Concurrent active infection including tuberculosis
Concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic immunosuppressants, systemic retinoids or ant-TNF agents
Severe comorbidities (diabetes mellitus requiring insulin, Q F of any severity, MI, unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary disease, history of cancer \*thin 5\_ years except cutaneous basal cell or squamous cell carcinoma or in situ cervical carcinoma, history of TB or TB exposure, chronic hepatitis B or C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
Currently enrolled or enrolled within 90 days prior in any trial for treatment of HS
Known HIV positive
Contraindication to etanercept as defined in package insert
Clareo Health | Treatment of Hidradenitis Suppurativa Using Etanercept
